Maker of weight-loss drugs to ask Trump to pause price negotiations: Report
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price negotiations that were put in place by the Biden administration's Inflation Reduction Act (IRA). "They need to fix [the IRA]," Eli Lilly CEO Dave Ricks told Bloomberg at the JPMorgan Healthcare Conference in San Francisco.
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on ...
GLP-1 medications like Ozempic, Wegovy, and Mounjaro are linked to reduced risks of dementia, heart failure, and severe ...
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
A new study found that GLP-1 medications like Ozempic can lower your risk for 42 conditions, including dementia. Here's what ...
Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss. GLP-1 medications were originally intended to ...
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback